NDA/BLA filedoutcome: unknownconf 0.70

reproxalap — NDA/BLA filed

$ALDX · Aldeyra Therapeutics, Inc. · dry eye disease

Event date

February 1, 2023

1221 days ago

Sponsor runway

38 mo

$65.0M liquid

Evidence

“In February 2023, the FDA accepted the reproxalap NDA for filing and set a Prescription Drug User Fee Act date of November 23, 2023.”

Source: 8-K filed 2023-11-28View on EDGAR ↗0001193125-23-283679

Ticker	Drug	Date	Outcome
$ALDX	reproxalap	2025-07-17	unknown
$ALDX	reproxalap	2024-11-01	unknown
$ALDX	reproxalap	2023-02-07	unknown

4 insiders · 1 buys · 0 sells

Buy

2023-04-12

Miller-Rich Nancy

Director

509 @ $10.13$5K

Grant

2023-02-28

Machatha Stephen

Chief Development Officer

220,258 @ ——

Grant

2023-02-28

Greenberg Bruce

See Remarks

110,028 @ ——

Grant

2023-02-28

Brady Todd C

President and CEO

238,750 @ ——

Grant

2023-02-28

Brady Todd C

President and CEO

250,000 @ ——

Date	Insider	Action	Shares	Price	Value
2023-04-12	Miller-Rich NancyDirector	Buy	509	$10.13	$5K
2023-02-28	Machatha StephenChief Development Officer	Grant	220,258	—	—
2023-02-28	Greenberg BruceSee Remarks	Grant	110,028	—	—
2023-02-28	Brady Todd CPresident and CEO	Grant	238,750	—	—
2023-02-28	Brady Todd CPresident and CEO	Grant	250,000	—	—